File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.molmed.2006.09.002
- Scopus: eid_2-s2.0-33750298090
- PMID: 16996801
- WOS: WOS:000242065300001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: PTEN in the haematopoietic system and its therapeutic indications
| Title | PTEN in the haematopoietic system and its therapeutic indications |
|---|---|
| Authors | |
| Issue Date | 2006 |
| Citation | Trends in Molecular Medicine, 2006, v. 12, n. 11, p. 503-505 How to Cite? |
| Abstract | A unique feature of the haematopoietic system is its self-renewal ability while maintaining a stable number of pluripotent haematopoietic stem cells (HSCs). Recently, two publications by Yilmaz and colleagues and Zhang and colleagues demonstrated that the loss of the tumour suppressor phosphatase and tensin homolog (PTEN) in mice disturbed the maintenance of quiescent HSCs and promoted leukemogenesis. Mammalian target of rapamycin (mTOR) inhibition with rapamycin distinctly rescued HSC development and depleted leukemic stem cells. Thus, the regulation of HSCs and leukemic cells seems to be governed by cell-context-dependent, PTEN-mediated regulation of mTOR. © 2006 Elsevier Ltd. All rights reserved. |
| Persistent Identifier | http://hdl.handle.net/10722/291765 |
| ISSN | 2021 Impact Factor: 15.272 2020 SCImago Journal Rankings: 3.789 |
| ISI Accession Number ID |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Cheung, Alison M. | - |
| dc.contributor.author | Mak, Tak W. | - |
| dc.date.accessioned | 2020-11-17T14:55:04Z | - |
| dc.date.available | 2020-11-17T14:55:04Z | - |
| dc.date.issued | 2006 | - |
| dc.identifier.citation | Trends in Molecular Medicine, 2006, v. 12, n. 11, p. 503-505 | - |
| dc.identifier.issn | 1471-4914 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/291765 | - |
| dc.description.abstract | A unique feature of the haematopoietic system is its self-renewal ability while maintaining a stable number of pluripotent haematopoietic stem cells (HSCs). Recently, two publications by Yilmaz and colleagues and Zhang and colleagues demonstrated that the loss of the tumour suppressor phosphatase and tensin homolog (PTEN) in mice disturbed the maintenance of quiescent HSCs and promoted leukemogenesis. Mammalian target of rapamycin (mTOR) inhibition with rapamycin distinctly rescued HSC development and depleted leukemic stem cells. Thus, the regulation of HSCs and leukemic cells seems to be governed by cell-context-dependent, PTEN-mediated regulation of mTOR. © 2006 Elsevier Ltd. All rights reserved. | - |
| dc.language | eng | - |
| dc.relation.ispartof | Trends in Molecular Medicine | - |
| dc.title | PTEN in the haematopoietic system and its therapeutic indications | - |
| dc.type | Article | - |
| dc.description.nature | link_to_subscribed_fulltext | - |
| dc.identifier.doi | 10.1016/j.molmed.2006.09.002 | - |
| dc.identifier.pmid | 16996801 | - |
| dc.identifier.scopus | eid_2-s2.0-33750298090 | - |
| dc.identifier.volume | 12 | - |
| dc.identifier.issue | 11 | - |
| dc.identifier.spage | 503 | - |
| dc.identifier.epage | 505 | - |
| dc.identifier.isi | WOS:000242065300001 | - |
| dc.identifier.issnl | 1471-4914 | - |